CORDIS
EU research results

CORDIS

English EN
Extracellular Proteases and the Cances Degradome: Innovative Diagnostic Markers, Therapeutic Targets and Tumour Imaging Agents

Extracellular Proteases and the Cances Degradome: Innovative Diagnostic Markers, Therapeutic Targets and Tumour Imaging Agents

Objective

The European Cancer Proteases Consortium (EUCPC) proposes multidisciplinary research into innovative approaches for cancer therapy and diagnosis based on the DEGRADOME - the repertoire of extracellular proteases through which cells regulate their local environment. Extracellular proteases remain an attractive target for intervention against cancer, even if first generation anti-protease drugs were disappointing in clinical trials. We now appreciate that proteases have complex roles with distinct functions at different stages of tumour development and progression, and may have conflicting effects on malignancy. We now propose to put these recent insights into pre-clinical and clinical settings. Using four common human malignancies - breast, prostate, colorectal and skin cancer - the EUCPC will employ a combination of strategies involving cell and mouse models, patient tissues, molecular profiling and modelling techniques, as well as physical and molecular imaging of tumours using MRI and PET. The 28 academic and 5 SME Participants combine expertise in genomics, bioinformatics, protein-protein interactions, proteomics, gene expression, molecular diagnostics and pathology, knockout mice and mouse models of cancer, synthetic chemistry, protein structure, drug development and tumour imaging. The EUCPC will facilitate access to shared technologies, data analysis and knowledge dissemination. In this 4 year Integrated Project the EUCPC aims to: 1) Define new molecular targets for drug design. 2) Develop novel specific interventions that are based on thorough knowledge of the pathophysiological roles of target proteases and related molecules, and understand how and when to use them. 3) Identify new molecular diagnostic and prognostic indicators of patient risk that can improve health care delivery based on an individualized, patient-oriented approach to therapy. 4) Provide new ways to enhance visualization of tumours in the clinic.

Coordinator

UNIVERSITY OF EAST ANGLIA

Address

University Plain
Norwich

United Kingdom

Administrative Contact

Dylan EDWARDS (Professor)

Participants (35)

Sort alphabetically

Expand all

THE FINSEN LABORATORY, COPENHAGEN UNIVERSITY HOSPITAL

Denmark

INSTITUTO FIRC DI ONCOLOGIA MOLECULARE

Italy

UNIVERSITÉ DE LIÈGE

Belgium

UNIVERSIDAD OVIEDO

Spain

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

KAROLINSKA INSTITUTET

Sweden

COMMISSARIAT A L'ENERGIE ATOMIQUE

France

UNIVERSITAIRE ZIEKENHUIZEN LEUVEN (GASTHUISBERG)

Belgium

UNIVERSITY OF TURKU

Finland

MEDICAL UNIVERSITY VIENNA

Austria

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS

Greece

STIFTELSEN CENTRUM FOR MOLEKULAR MEDICIN/ CENTER FOR MOLECULAR MEDICINE FOUNDATION

Sweden

UNIVERSITY OF FREIBURG

Germany

NATIONAL INSTITUTE OF BIOLOGY

Slovenia

ISTITUTO DI RICERCHE FARMACOLOGICHE "MARIO NEGRI"

Italy

UNIVERSITAETSKLINIKUM HEIDELBERG

Germany

UNIVERSITY OF GLASGOW

United Kingdom

CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET EN MEDICINE (GIE)

France

TECHNICAL UNIVERSITY OF MUNICH

Germany

PROTEROS BIOSTRUCTURES GMBH

Germany

DEUTSCHES KREBSFORSCHUNGSZENTRUM

Germany

UNIVERSITY OF AARHUS

Denmark

INSTITUTE OF GENETICS AND BIOPHYSICS "ADRIANO BUZZATI-TRAVERSO", NATIONAL RESEARCH COUNCIL

Italy

ISTITUTO DI ENDOCRINOLOGIA E ONCOLOGIA SPERIMENTALE "G.SALVATORE", CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Spain

QUEEN MARY, UNIVERSITY OF LONDON

United Kingdom

ONCOMETHYLOME SCIENCES S.A. (EX-ONCOGENOME SCIENCES S.A.)

Belgium

GENOPTICS S.A.

France

UNIVERSITEIT GENT

Belgium

KRKA D.D., PHARMACEUTICAL COMPANY

Slovenia

INSTITUTE OF PATHOLOGY, CANTONAL HOSPITAL, UNIVERSITY OF BASEL

Switzerland

HUMBOLDT UNIVERSITY

Germany

UNIVERSITY OF SOUTHAMPTON

United Kingdom

GNOTHIS AB

Sweden

MAX-PLANCK-SOCIETY FOR THE ADVANCEMENT OF SCIENCE

Germany

Project information

Grant agreement ID: 503297

  • Start date

    1 January 2004

  • End date

    31 December 2007

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 13 420 400

  • EU contribution

    € 10 185 000

Coordinated by:

UNIVERSITY OF EAST ANGLIA

United Kingdom